A new potential biomarker raises concerns over the current standard for treating COVID-19 induced blood clots with high dose blood thinners.

Study finds NAD+ break down leads to multi organ scarring, providing now a previously undiscovered pathogenic role of the enzyme CD38 in disease scarring.

Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.

A new study reveals the virus triggers production of antibodies circulating through the blood, causing clots in people hospitalized with the disease.

The updated 2020 guidelines from the American College of Rheumatology focus on establishing a standard treat-to-target urate lowering therapy.

Researchers find that a protein in the skin of patients with lupus enables staph bacteria to stick to their skin.